イシハラ　ヒロキ   Ishihara Hiroki   石原　弘喜    所属   医学部 医学科（東京女子医科大学病院）    職種   助教
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer.
掲載誌名	正式名：Japanese journal of clinical oncology 略　 称：Jpn J Clin Oncol ISSNコード：14653621/03682811
掲載区分	国外
巻・号・頁	50(8),pp.933-939
著者・共著者	IKEDA Takashi†, ISHIHARA Hiroki, IIZUKA Junpei*, HASHIMOTO Yasunobu, YOSHIDA Kazuhiko, KAKUTA Yoichi, TAKAGI Toshio, OKUMI Masayoshi, ISHIDA Hideki, KONDO Tsunenori, TANABE KAZUNARI*
担当区分	2nd著者
発行年月	2020/08
概要	BACKGROUND:Cancer cachexia is associated with a poor prognosis. This study aimed to investigate the association between sarcopenia and survival in patients with metastatic hormone-sensitive prostate cancer.RESULTS:In total, 163 patients (82.7%) had sarcopenia. Cancer-specific survival and overall survival were significantly shorter in sarcopenic patients than in non-sarcopenic patients (median cancer-specific survival: 77.0 months vs. not reached, P = 0.0099; overall survival: 72.0 months vs. not reached, P = 0.0465), whereas castration-resistance prostate cancer-free survival did not significantly differ between the groups (P = 0.6063). Multivariate analyses showed that sarcopenia was an independent factor for cancer-specific survival (hazard ratio: 2.18, P = 0.0451), together with the Gleason score (hazard ratio: 1.87, P = 0.0272) and LATITUDE risk classification (hazard ratio: 2.73, P = 0.0008). Moreover, the prognostic association of sarcopenia was remarkable in patients aged <73.0 years (cancer-specific survival: 82.0 months vs. not reached, P = 0.0027; overall survival: 72.0 months vs. not reached, P = 0.0078 in sarcopenic vs. non-sarcopenic patients), whereas the association was not significant in patients aged ≥73.0 years (cancer-specific survival: 76.0 and 75.0 months, respectively, P = 0.7879; overall survival: 67.0 and 52.0 months, respec
DOI	10.1093/jjco/hyaa045
PMID	32303747